Conditions: Non Small Cell Lung Cancer
Keywords: Lung Cancer (NSCLC)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Ixabepilone intervention 2: Cisplatin intervention 3: Ixabepilone intervention 4: Cisplatin
Intervention descriptions: intervention 1: Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months intervention 2: Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months intervention 3: Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months intervention 4: Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months

Protocol document: